Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies.

The Journal of steroid biochemistry and molecular biology·2024
Same author

Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models.

Nature communications·2023
Same author

Cancer-associated fibroblasts of the prostate promote a compliant and more invasive phenotype in benign prostate epithelial cells.

Materials today. Bio·2020
Same author

DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation.

Cell death and differentiation·2014
Same author

Breaking through a roadblock in prostate cancer research: an update on human model systems.

The Journal of steroid biochemistry and molecular biology·2012
Same author

Prostate-regenerating capacity of cultured human adult prostate epithelial cells.

Cells, tissues, organs·2009

Related Experiment Video

Updated: Jul 17, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

Published on: May 16, 2012

Aromatase and prostate cancer.

S J Ellem1, G P Risbridger

  • 1Centre for Urological Research, Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia.

Minerva Endocrinologica
|February 25, 2006
PubMed
Summary

Estrogens, produced by aromatase, may play a role in prostate disease development. Studies using aromatase knockout (ArKO) and over-expressing (AROM+) mice aim to clarify estrogen

Area of Science:

  • Endocrinology
  • Urology
  • Oncology

Background:

  • Androgens are crucial for prostate growth but also risk factors for prostate disease.
  • Prostate disease incidence rises with age despite declining androgen levels, suggesting other hormonal influences.
  • Estrogens and their receptors are present in the prostate, indicating direct gland response.

Purpose of the Study:

  • To investigate the role of estrogens and aromatase in prostate disease.
  • To understand the contribution of aromatase expression to prostate carcinogenesis.
  • To utilize transgenic mouse models to examine aromatase function in the prostate.

Main Methods:

  • Analysis of aromatase expression in benign and malignant prostate tissues.
  • Utilizing aromatase knockout (ArKO) and aromatase over-expressing (AROM+) mouse models.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 19, 2013

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Related Experiment Videos

Last Updated: Jul 17, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

Published on: May 16, 2012

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 19, 2013

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

  • Examining the effects of high-dose estrogens and androgens on prostate tissue.

    • Main Results:

    • Aromatase is expressed in the stroma of benign prostate tissue.
    • Epithelial aromatase expression is induced in prostate malignancy with altered promoter use.
    • High-dose estrogens can induce premalignant dysplasia, and combined with high-dose androgens, can cause malignancy.

    Conclusions:

    • Aberrant aromatase expression is linked to prostate disease.
    • Estrogens may play a significant role in prostate carcinogenesis.
    • Transgenic mouse models are essential for understanding aromatase and estrogen's role in prostate disease.